Canopus Bioscience ltd.
CTC (Circulating Tumor Cell) technology (patent pending) is an enabling platform technology for the recovery and analysis of disseminated cancer cells in peripheral blood. Capitalizing on recent advances in disease marker discovery, single cell analysis, and patient-specific therapeutics our CTC technology provides a high sensitivity, high specificity, repeatable, reproducible, and non-invasive diagnostic assay for guiding treatment decisions and improved patient triage.
Cells Retrieved By Canopus Bioscience's CTC Enrichment Technology
Clinical research on a range of cancer types has demonstrated that the presence and number of CTCs is a useful diagnostic indicator of metastatic potential. Recent literature suggests that tumor cells may disseminate in a far less progressed genomic state than what was previously thought, only later acquiring genomic aberrations typical of metastatic cells. The early detection followed by early treatment of cancer equates to an improved survival and decreased morbidity. Our CTC technology when combined with immunochemical staining for disease-specific markers provides a powerful diagnostic indicator for patient-tailored treatment. An example is the detection of Her2neu over-expression indicating an aggressive but potentially treatable form of breast cancer.
Moreover, the Canopus CTC
technology can be applied to treatment monitoring by repeat sampling
and enumeration of the CTC burden in patient blood samples.
Our enrichment process removes all the red blood cells and reduces the number of white blood cells (leukocytes) to nominally 50,000 cells (1000:1 enrichment) for 4-5ml of blood.
The enriched sample can then either be presented as a single mono-layer slide or fed through an imaging flow cytometer.
The CTC technology produces an enriched specimen that maintains cell morphology and is compatible with any immunocytochemical staining technique. It can also be coupled with complementary technologies, leveraging recent advances made in disease marker discovery, single cell analysis, and patient-specific therapeutics. Currently, Canopus has demonstrated effectiveness with non-specific cancer markers and with markers specific to breast cells. This enabling technology bridges a crucial gap between patient-specific disease etiology and patient-tailored treatment options.
Molecular diagnostic products have limitations that restrict their widespread market acceptance:
push to develop targeted therapies is the most notable trend in
oncology since the introduction of cell-killing treatments. A
significant number of cell-specific and patient-specific therapies have
reached late-phase trials and have even been marketed (e.g.
Gleevec® and Herceptin®), raising expectations that
similar treatments can play a major role in cancer care. However, major
challenges remain in target definition and patient selection. To
address these challenges, many targeted drugs will require
cell-specific biomarker-based diagnostic tests. Consequently, it is
anticipated that the theranostic market, or
therapeutics coupled to specific diagnostic tests, will achieve
significant growth in the coming years.
Recently Veridex a J&J company received a 510k for what in the past was considered by FDA to be a Class III device. This has significantly reduced the cost of entry into the market! The resulting test for the management of metastatic breast cancer is estimated to have a $300 million per year market value.
In general, any tumor types that disseminate cells into the bloodstream are good candidates for both detection and disease monitoring. These include breast cancer, malignant melanoma, prostate cancer, lung cancer, gastrointestinal cancers and pancreatic cancer.
Of special interest:
Canopus Bioscience welcomes inquiries from potential research, licensing or marketing partners.For additional information please email: email@example.com